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Abstract 
 
Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M) is the most common form 
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of systemic hereditary amyloidosis, inherited in autosomal dominant mode. The disease, also 
called familial amyloid polyneuropathy type I (FAP-I), is caused by a mutant transthyretin (TTR) 
protein, which is synthesized by the liver. A single amino acid substitution of methionine for 
valine at position 30 of the TTR molecule (TTR V30M) was found in Portuguese patients. The 
clinical disease usually manifests as a peripheral sensory, motor and autonomic neuropathy 
starting in the 3rd or 4th decade of life. Renal manifestations of ATTR V30M, like other 
amyloidoses, are different levels of proteinuria and renal insufficiency. In ATTR V30M a large 
amyloid deposition in the medullary zone of the kidney and tubules is characteristic. A more 
extensive glomerular and vascular involvement is present only in patients with renal 
manifestations. A prospective survey in the north of Portugal showed that a stage of 
microalbuminuria (MA) could precede nephropathy and neurological disease. Nephropathy in 
FAP-I is present in one-third of affected patients and tends to aggregate in families. The 
progression towards end-stage renal disease (ESRD) affects 10% of the patients, and the 
survival after initiation of dialysis is a mean of 21 months. Patients who progress to ESRD have 
a late onset of neuropathy and lower prevalence of clinical disease in their families. Liver 
transplantation is a widely accepted treatment for FAP-I, and combined liver-kidney 
transplantation is also an option for selected patients with FAP-I and ESRD.
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